Nuray Aktay Ayaz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8901836/publications.pdf

Version: 2024-02-01

123 papers 1,518 citations

430874 18 h-index 395702 33 g-index

127 all docs

127 docs citations

times ranked

127

1853 citing authors

#	Article	IF	Citations
1	Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine: Table 1 Journal of Rheumatology, 2011, 38, 516-518.	2.0	132
2	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
3	Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2790-2800.e15.	3.8	112
4	Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clinical Rheumatology, 2010, 29, 209-210.	2.2	94
5	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 994-1001.	2.0	59
6	Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clinical Rheumatology, 2008, 27, 1317-1320.	2.2	55
7	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	1.8	50
8	Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. Rheumatology International, 2019, 39, 911-919.	3.0	37
9	Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatology International, 2022, 42, 879-889.	3.0	35
10	The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clinical and Experimental Rheumatology, 2011, 29, 111-6.	0.8	35
11	Behçet disease: treatment of vascular involvement in children. European Journal of Pediatrics, 2010, 169, 427-430.	2.7	33
12	Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19. Rheumatology International, 2020, 40, 1613-1623.	3.0	32
13	The clinical spectrum of Henoch–Schönlein purpura in children: a single-center study. Clinical Rheumatology, 2019, 38, 1707-1714.	2.2	30
14	Comorbidities and phenotype–genotype correlation in children with familial Mediterranean fever. Rheumatology International, 2021, 41, 113-120.	3.0	30
15	Musculoskeletal sonography in juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 61, 58-60.	6.7	27
16	Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort. Frontiers in Pediatrics, 2021, 9, 805919.	1.9	22
17	A novel assessment tool for clinical care of patients with autoinflammatory disease: juvenile autoinflammatory disease multidimensional assessment report. Clinical and Experimental Rheumatology, 2016, 34, 129-135.	0.8	22
18	Preventing tuberculosis in children receiving anti-tnf treatment. Clinical Rheumatology, 2010, 29, 389-392.	2.2	20

#	Article	IF	Citations
19	Factor VII Deficiency. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 588-593.	1.7	19
20	Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever – a randomized controlled noninferiority trial. Arthritis Research and Therapy, 2016, 18, 85.	3.5	18
21	Characteristics of pediatric Behçet's disease in Turkey and Israel: A cross-sectional cohort comparison. Seminars in Arthritis and Rheumatism, 2020, 50, 515-520.	3.4	18
22	The evaluation of anxiety, depression and quality of life scores of children and adolescents with familial Mediterranean fever. Rheumatology International, 2020, 40, 757-763.	3.0	18
23	Subtype frequencies, demographic features, and remission rates in juvenile idiopathic arthritis - 265 cases from a Turkish center. Turkish Journal of Pediatrics, 2017, 59, 548-554.	0.6	18
24	Performance of Tel-Hashomer, Livneh, pediatric and new Eurofever/PRINTO classification criteria for familial Mediterranean fever in a referral center. Rheumatology International, 2020, 40, 21-27.	3.0	17
25	ADA2 Deficiency: Case Series of Five Patients with Varying Phenotypes. Journal of Clinical Immunology, 2020, 40, 253-258.	3.8	17
26	Leflunomide treatment in juvenile idiopathic arthritis. Rheumatology International, 2019, 39, 1615-1619.	3.0	16
27	The relevance of practical laboratory markers in predicting gastrointestinal and renal involvement in children with Henoch–Schönlein Purpura. Postgraduate Medicine, 2021, 133, 272-277.	2.0	16
28	The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. Rheumatology International, 2022, 42, 469-475.	3.0	16
29	Etiologic Spectrum and Follow-Up Results of Noninfectious Uveitis in Children: A Single Referral Center Experience. Archives of Rheumatology, 2019, 34, 294-300.	0.9	15
30	Nailfold capillaroscopy: A sensitive method for evaluating microvascular involvement in children with SARS-CoV-2 infection. Microvascular Research, 2021, 138, 104196.	2.5	14
31	Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Rheumatology, 2022, 61, 4482-4490.	1.9	14
32	Genotoxicity of anti–tumor necrosis factor therapy in patients with juvenile idiopathic arthritis. Arthritis Care and Research, 2010, 62, 73-77.	3.4	12
33	Short-term follow-up results of children with familial Mediterranean fever after cessation of colchicine: is it possible to quit?. Rheumatology, 2019, 58, 1818-1821.	1.9	12
34	The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis. Modern Rheumatology, 2020, 30, 900-904.	1.8	12
35	Age of onset as an influencing factor for disease severity in children with familial Mediterranean fever. Modern Rheumatology, 2021, 31, 219-222.	1.8	12
36	Systemic lupus erythematosus complicated with Castleman disease: a case-based review. Rheumatology International, 2021, 41, 475-479.	3.0	11

#	Article	IF	CITATIONS
37	Canakinumab in colchicine resistant familial mediterranean fever and other pediatric rheumatic diseases. Turkish Journal of Pediatrics, 2020, 62, 167.	0.6	10
38	How useful are Kawasaki disease risk scoring systems to the Turkish population?. Anatolian Journal of Cardiology, 2020, 24, 97-106.	0.9	10
39	Profile of new referrals to a single pediatric rheumatology center in Turkey. Rheumatology International, 2020, 40, 313-321.	3.0	9
40	Genetic panel screening in patients with clinically unclassified systemic autoinflammatory diseases. Clinical Rheumatology, 2020, 39, 3733-3745.	2.2	9
41	Comparison of the clinical diagnostic criteria and the results of the next-generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases. Clinical Rheumatology, 2021, 40, 2327-2337.	2.2	9
42	The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods. Journal of Clinical Rheumatology, 2021, 27, 1-4.	0.9	9
43	Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study. Lupus, 2021, 30, 1983-1990.	1.6	9
44	Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus, 2021, 30, 2144-2150.	1.6	9
45	Cochlear functions in children with familial Mediterranean fever: Any role of the severity of the disease?. International Journal of Pediatric Otorhinolaryngology, 2015, 79, 1566-1570.	1.0	8
46	Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. Rheumatology International, 2020, 40, 1111-1116.	3.0	8
47	Is there any difference regarding atopy between children with familial Mediterranean fever and healthy controls?. Allergologia Et Immunopathologia, 2017, 45, 549-552.	1.7	7
48	Rheumatic diseases in Syrian refugee children: a retrospective multicentric study in Turkey. Rheumatology International, 2020, 40, 583-589.	3.0	7
49	The readiness of pediatric rheumatology patients and their parents to transition to adultâ€oriented treatment. International Journal of Rheumatic Diseases, 2021, 24, 397-401.	1.9	7
50	Comparison of Pediatric Familial Mediterranean Fever Patients Carrying Only E148Q Variant With the Ones Carrying Homozygous Pathogenic Mutations. Journal of Clinical Rheumatology, 2021, 27, 182-186.	0.9	7
51	Coexistence of early onset sarcoidosis and partial interferon- \hat{I}^3 receptor 1 deficiency. Turkish Journal of Pediatrics, 2016, 58, 545-549.	0.6	7
52	Clinical experiences in turkish paediatric patients with chronic recurrent multifocal osteomyelitis. Turkish Journal of Pediatrics, 2019, 61, 879.	0.6	7
53	Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey. Vaccine, 2022, 40, 1829-1836.	3.8	7
54	Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy. International Journal of Hematology, 2014, 99, 706-713.	1.6	6

#	Article	IF	CITATIONS
55	Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections. Clinical Rheumatology, 2020, 39, 249-253.	2.2	6
56	Kawasaki disease shock syndrome: a rare and severe complication of Kawasaki disease. Turkish Journal of Pediatrics, 2016, 58, 415-418.	0.6	6
57	Time to collaborate: Objectives, Design, and Methodology of PeRA-Research Group. İstanbul Kuzey Klinikleri, 2020, 8, 200-202.	0.3	6
58	The Multifaceted Presentation of the Multisystem Inflammatory Syndrome in Children: Data from a Cluster Analysis. Journal of Clinical Medicine, 2022, 11, 1742.	2.4	6
59	Familial Mediterranean Fever: Diagnosing as Early as 3 Months of Age. Case Reports in Pediatrics, 2014, 2014, 1-3.	0.4	5
60	Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatology International, 2020, 40, 771-776.	3.0	5
61	Isotretinoin―nduced sacroiliitis: Case series of four patients and a systematic review of the literature. Pediatric Dermatology, 2020, 37, 171-175.	0.9	5
62	Corticosteroid-resistant anakinra-responsive protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever. İstanbul Kuzey Klinikleri, 2019, 7, 78-80.	0.3	5
63	A Case of Kawasaki Disease With Severe Lip and Oral Mucosa Involvement Complicated With Microstomia and Corrected With Surgery. Archives of Rheumatology, 2018, 33, 238-240.	0.9	5
64	Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opinion on Biological Therapy, 2022, 22, 197-202.	3.1	5
65	Time to focus on outcome assessment tools for childhood vasculitis. Pediatric Rheumatology, 2011, 9, 29.	2.1	4
66	Surgical interventions in childhood rare factor deficiencies. Blood Coagulation and Fibrinolysis, 2013, 24, 854-861.	1.0	4
67	Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging. Case Reports in Pediatrics, 2015, 2015, 1-4.	0.4	4
68	How do we encounter rare factor deficiencies in children? Single-centre results from Turkey. Blood Coagulation and Fibrinolysis, 2015, 26, 145-151.	1.0	4
69	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 395-402.	3.0	4
70	Does familial Mediterranean fever affect cognitive function in children? Electrophysiological preliminary study. International Journal of Neuroscience, 2018, 128, 10-14.	1.6	4
71	Comorbidities of antiphospholipid syndrome and systemic lupus erythematosus in children. Current Rheumatology Reports, 2020, 22, 21.	4.7	4
72	The influence of carrying MEFV gene variants on juvenile systemic lupus erythematosus. Rheumatology International, 2021, 41, 157-161.	3.0	4

#	Article	IF	Citations
73	Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey. Rheumatology International, 2021, , 1.	3.0	4
74	Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience. Rheumatology International, $2021, 1.$	3.0	4
7 5	Sacroiliitis in children and adolescents with familial Mediterranean fever. Advances in Rheumatology, 2021, 61, 29.	1.7	4
76	Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil. Turkish Journal of Pediatrics, 2019, 61, 771.	0.6	4
77	Performance of recent PRINTO criteria versus current ILAR criteria for systemic juvenile idiopathic arthritis: A single-centre experience. Modern Rheumatology, 2023, 33, 187-193.	1.8	4
78	The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2021, 39, 118-123.	0.8	4
79	Anterior Segment Analysis and Evaluation of Corneal Biomechanical Properties in Children with Joint Hypermobility. Týrk Oftalmoloji Dergisi, 2020, 50, 71-74.	0.9	3
80	Cluster Analysis of Pediatric Behçet's Disease: Data from The Pediatric Rheumatology Academy (PeRA)-Research Group (RG). Modern Rheumatology, 2022, , .	1.8	3
81	Why is the frequency of uveitis low in Turkish children with juvenile idiopathic arthritis?. Rheumatology, 2019, 59, 679-680.	1.9	2
82	Neuroimaging of Children With Takayasu Arteritis. Journal of Child Neurology, 2021, 36, 642-647.	1.4	2
83	Sustained hyperferritinemia in a child with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis - perforinopathy: case based review. Turkish Journal of Pediatrics, 2018, 60, 598.	0.6	2
84	The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. İstanbul Kuzey Klinikleri, 2019, 7, 118-123.	0.3	2
85	Validity and reliability of four parent/patient reported outcome measures for juvenile idiopathic arthritis remote monitoring. Arthritis Care and Research, 2022, , .	3.4	2
86	Is it all about age? Clinical characteristics of Kawasaki disease in the extremely young: PeRA research group experience. Postgraduate Medicine, 2022, 134, 429-434.	2.0	2
87	FRIO536â€FAMILIAL MEDITERRANEAN FEVER (FMF): A SINGLE CENTEREXPERIENCE FROM TURKEY. , 2019, , .		1
88	THU0524â€ARE CHILDREN AND ADULTS HAVING DIFFERENT PHENOTYPE AND GENOTYPE OF FMF?. , 2019, , .		1
89	Differential diagnosis portfolio of a pediatric rheumatologist: eight cases, eight stories. Clinical Rheumatology, 2021, 40, 769-774.	2.2	1
90	Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis. Rheumatology International, 2021 , , 1 .	3.0	1

#	Article	IF	Citations
91	Comment on: Clinical significance of E148Q heterozygous variant in paediatric Familial Mediterranean Fever. Rheumatology, 2021, 60, e294-e295.	1.9	1
92	A case of chickenpox complicated with subacute osteomyelitis. Marmara Medical Journal, 2016, 29, 110.	0.8	1
93	Orbital muscle involvement in a child with familial Mediterranean fever. Marmara Medical Journal, 2016, 29, 124.	0.8	1
94	Immunodeficiency-Like Phenotype, Recurrent Pulmonary Manifestations, and Persistent Polyarthritis: Mevalonate Kinase Deficiency Successfully Treated With Adalimumab. Archives of Rheumatology, 2020, 35, 627-628.	0.9	1
95	Editorial: Hereditary Periodic Fevers and Autoinflammatory Diseases. Frontiers in Pediatrics, 2022, 10, 855738.	1.9	1
96	Autoimmune and autoinflammatory diseases with mucocutaneous manifestations: A pediatric rheumatology perspective. International Journal of Dermatology, 2023, 62, 723-736.	1.0	1
97	Dissecting the heterogeneity of macrophage activation syndrome. Pediatric Rheumatology, 2014, 12, .	2.1	0
98	How Pricing And Reimbursement Policies Affect The Budget Impact of The Treatment of Systemic Juvenile Idiopathic Arthritis In Turkey. Value in Health, 2015, 18, A643.	0.3	0
99	Comment on: Short-term follow-up results of children with familial Mediterranean fever after cessation of colchicine: is it possible to quit?: reply. Rheumatology, 2019, 58, 1886-1887.	1.9	0
100	THU0291â€THE CHARACTERISTICS OF PEDIATRIC BEHÇET'S DISEASE IN TURKEY VERSUS ISRAEL. , 2019,	, .	0
101	SAT0522â€COMPARISON OF CHILDREN CARRYING E148Q VARIANT WITH CHILDREN CARRYING HOMOZYGO PATHOGENIC VARIANTS. , 2019, , .	JS	0
102	AB0991â€PRELIMINARY RESULTS OF REFERRALS TO A TERTIARY PEDIATRIC RHEUMATOLOGY OUTPATIENT CLI A YEAR IN REVIEW., 2019,,.	NIC:	0
103	AB0990â€FINAL DIAGNOSIS OF THE PATIENTS WITH MUSCULOSKELETAL COMPLAINTS: PRELIMINARY RESULT OF ONE-YEAR STUDY. , 2019, , .	S	0
104	AB1055â€FINAL DIAGNOSES OF THE PATIENTS WHO WERE REFERRED TO A TERTIARY PEDIATRIC RHEUMATOLOGY OUTPATIENT CLINIC FOR LABORATORY ABNORMALITIES. , 2019, , .		0
105	AB0594â€THE CLINICAL SPECTRUM OF HENOCH-SCHÖNLEIN PURPURA IN CHILDREN: A PROSPECTIVE SINGLE-CENTER STUDY. , 2019, , .		0
106	AB1061â€SHORT TERM FOLLOW-UP RESULTS OF CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER AFTER CESSATION OF COLCHICINE: IS IT POSSIBLE TO QUIT?. , 2019, , .		0
107	SATO483â€COMPARISON OF THE CLINICAL DIAGNOSTIC CRITERIA AND RESULTS OF THE NEXT GENERATION SEQUENCE GENE PANEL IN PATIENTS WITH PERIODIC FEVER. , 2019, , .		0
108	FRIO556â€GENETIC SCREENING IN PATIENTS WITH UNDIFFERENTIATED PERIODIC FEVER SYNDROME. , 2019, ,		0

#	Article	IF	Citations
109	Coexistence of Juvenile Systemic Lupus Erythematosus and Juvenile Spondyloarthropathy: A Case Report and Review of the Literature. Archives of Rheumatology, 2020, 35, 132-136.	0.9	0
110	Comment on â€~Age dependent safety and efficacy of colchicine treatment for familial Mediterranean fever in children'. Seminars in Arthritis and Rheumatism, 2020, 50, 1552.	3.4	0
111	Response to †How to define disease severity accurately in patients with familial Mediterranean fever'. Rheumatology International, 2021, 41, 239-240.	3.0	0
112	Evaluation of Children Referred to Pediatric Rheumatology Outpatient Clinic with Suspicious Laboratory Test Results. İstanbul Kanuni Sultan Süleyman Tıp Dergisi, 2021, , .	0.0	0
113	We might have the same mutation but my inflammasome beats your inflammasome: CINCA versus FCAS. ReumatologÃa ClÃnica, 2021, 17, 118-119.	0.5	0
114	Granulocyte Transfusion in Febrile Neutropenia. Blood, 2015, 126, 4612-4612.	1.4	0
115	Leptospirosis in a child with acute respiratory distress syndrome. Turkish Journal of Pediatrics, 2017, 59, 688.	0.6	0
116	An extreme entity in differential diagnosis of musculoskeletal involvement-fibrodysplasia ossificans progressiva: a case based review. Turkish Journal of Pediatrics, 2018, 60, 593.	0.6	0
117	Towards a combined pediatric rheumatology-dermatology clinic: One-year experience. İstanbul Kuzey Klinikleri, 2020, 8, 37-41.	0.3	0
118	Like †North Americans', †Europeans', or †Others': Where do Turkish children with juvenile idioparthritis stand in the new classification system?. İstanbul Kuzey Klinikleri, 2020, 8, 421-422.	oathic 0.3	0
119	Otoinflamatuar Periyodik Ateş Sendromları. The Journal of Child, 2020, 20, .	0.2	0
120	The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 118-123.	0.8	0
121	What is the Role of Mucocutaneous Manifestations in the Clinical Presentation of Monogenic Autoinflammatory Diseases? A Singlecenter Experience. Bagcilar Medical Bulletin, 2022, 7, 70-76.	0.1	0
122	Is There an Association Between Initial Clinical Manifestations and the Development of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis?. Medical Journal of Bakirkoy, 2022, 18, 31-36.	0.1	0
123	Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars. BioDrugs, 2022, , 1.	4.6	0